The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Nov. 02, 2021

Filed:

Jul. 03, 2018
Applicant:

Medtronic Ardian Luxembourg S.a.r.l., Luxembourg, LU;

Inventors:

Marcia Gallagher, Santa Rosa, CA (US);

Douglas Hettrick, Santa Rosa, CA (US);

Assignee:
Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61N 1/36 (2006.01); A61B 18/02 (2006.01); A61N 1/05 (2006.01); A61B 18/04 (2006.01); A61N 7/00 (2006.01); A61B 18/18 (2006.01); A61N 2/00 (2006.01); A61B 18/00 (2006.01); A61B 18/08 (2006.01); A61B 18/22 (2006.01);
U.S. Cl.
CPC ...
A61N 1/36096 (2013.01); A61B 18/02 (2013.01); A61N 1/0551 (2013.01); A61B 18/04 (2013.01); A61B 18/08 (2013.01); A61B 18/18 (2013.01); A61B 18/22 (2013.01); A61B 2018/0022 (2013.01); A61B 2018/00434 (2013.01); A61B 2018/00511 (2013.01); A61B 2018/00577 (2013.01); A61B 2018/00666 (2013.01); A61B 2018/00791 (2013.01); A61B 2018/00875 (2013.01); A61B 2018/0212 (2013.01); A61N 2/006 (2013.01); A61N 7/00 (2013.01);
Abstract

Methods for treating post-traumatic stress disorder (PTSD) and/or for reducing a risk associated with developing PTSD in patients via therapeutic renal neuromodulation and associated systems are disclosed herein. Sympathetic nerve activity can contribute to several cellular and physiological conditions associated with PTSD as well as an increased risk of developing PTSD following a traumatic event. One aspect of the present technology is directed to methods for improving a patient's calculated risk score corresponding to a PTSD status in the patient. Other aspects are directed to reducing a likelihood of developing PTSD in patients presenting one or more PTSD risk factors. Renal sympathetic nerve activity can be attenuated to improve a patient's PTSD status or risk of developing PTSD. The attenuation can be achieved, for example, using an intravascularly positioned catheter carrying a therapeutic assembly configured to use, e.g., electrically-induced, thermally-induced, and/or chemically-induced approaches to modulate the renal sympathetic nerve.


Find Patent Forward Citations

Loading…